Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Jun 20;77(6):910–916. doi: 10.1093/cid/ciad304

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

PMC Copyright notice

Figure 2. — Development nAb titers for intradermal (ID) and intramuscular (IM) vaccination: Titers of rabies neutralizing antibodies (nAb) measured by fluorescent antibody virus neutralization test (FAVNT) at baseline (D0), 14 d (D14) and 28 d (D28) after initial rabies vaccination either via ID (green) or IM administration (blue). A, Overall nAb development for full study cohort (n = 203, ID: 108, IM: 95). B, Results of nAb development stratified by age into children of 2–11 y (n = 65; ID: 41, IM: 24), teenagers of 12–17 y (n = 29; ID: 11, IM: 18), and adults of ≥17 y (n = 109; ID: 56, IM: 53). Each dot represents a single individual. Red lines represent median and interquartile range for each group. Dashed line indicates the threshold for seroprotection at 0.5 IU/mL. Statistics: Kruskal–Wallis with Dunn correction for multiple comparisons. *P < .05 **P ≤ .01, **P ≤ .001 and ****P ≤ .0001.